A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

Women with autoimmune diseases are more likely than men to get told that their symptoms were merely psychological, resulting in longer delays and timely treatment.

A new international study published in The Lancet’s eClinicalMedicine studied the diagnostic experiences of 6,607 people living with autoimmune diseases.

Researchers from the University of Cambridge and the University of East Anglia found that 43% of women reported that their symptoms had previously been attributed to psychiatric causes, compared to 33% of men.

Women were also more likely to report being told their physical symptoms were psychosomatic, meaning they were caused by psychological factors. This was reported by 34% of women, compared to 22% of men.

After accounting for factors like age, disease group, continent and household finances, women were nearly 50% more likely to report a psychiatric misdiagnosis and almost 75% more likely to report a psychosomatic misdiagnosis than men.

The findings highlight gender disparities patients with autoimmune conditions experience during the diagnostic process, especially when the condition is not immediately ascertainable through clinical tests.

Women Report Longer Delays In Diagnosis

Also read: World Arthritis Day - Arthritis At 42, 62 & Even 15: How Treatment & Rehabilitation Help Patients Regain Mobility

The study also found differences in how long patients waited between the onset of symptoms and receiving an autoimmune disease diagnosis.

Among women, the most frequently reported time to diagnosis was one to two years. For men, the most common interval was less than three months. Women also reported attending more healthcare consultations before receiving a diagnosis.

“Patients with autoimmune diseases can present with symptoms that can initially be difficult to explain medically, and sometimes it can take months or years before a diagnosis becomes clear,” said Dr Melanie Sloan, from the University of Cambridge and the University of East Anglia.

“Our findings highlight that psychological or mental health explanations can be given too soon. This is true for both sexes, but our study suggests that females may be particularly vulnerable to these types of misdiagnoses,” she added.

Autoimmune diseases develop when the immune system mistakenly attacks the body's own tissues. For example, conditions like lupus, rheumatoid arthritis and multiple sclerosis. Statistically, women are more likely to develop autoimmune diseases than men.

Diagnosis can be challenging because early symptoms may include fatigue, persistent pain, sleep disturbances and low mood. These symptoms are common in other conditions, may fluctuate over time and can affect multiple parts of the body.

Patient Accounts As Important As Medical Records

The researchers said that patient accounts are important because medical records may not capture the full diagnostic journey, including when symptoms first appeared or how patients experienced consultations.

Shaista Tayabali, a patient partner and co-author of the study, said, “The differences between the sexes in misdiagnoses for people with autoimmune diseases is stark. The fact that females reported higher rates of psychiatric and psychosomatic misdiagnoses than males, yet reported lower misdiagnoses for other physical diseases, suggests that historical gender biases remain a challenging aspect of the diagnostic journey.”

The researchers stressed that the findings do not mean psychological diagnoses are always incorrect. People can have both autoimmune and mental health conditions, and some autoimmune diseases, including lupus, can themselves affect the brain.

The team called for clinicians to remain alert to possible autoimmune conditions, acknowledge diagnostic uncertainty and reassess patients when symptoms persist.

A 46-year-old mother of six in Oregon, US, lost both legs and suffered multiple life-altering injuries after developing a severe infection following a hysterectomy.

According to a lawsuit alleging medical negligence, Trisha Stevens underwent the hysterectomy in October 2024. The lawsuit alleges that her infection was not diagnosed on time and treated promptly, which eventually led to peritonitis, septic shock and multiple organ failure.

Stevens and her husband are seeking $68.5 million in damages from several doctors and Legacy Health. The allegations have not been established in court yet.

Stevens lost both legs above the knees, her right hand and parts of her left hand. She also lost parts of her lips and tongue and suffered spinal cord damage that left her paralysed from the waist down.

“I came home having lost both of my legs and my right hand. My left hand was left unusable after the necrosis. I lost parts of my lips and tongue, and I live with paralysis in a body that no longer responds the way it once did,” Stevens told local news outlet KGW.

Her husband, Brian, now cares for her as she navigates the physical, mental and emotional consequences of the sepsis.

What Is Sepsis?

Also read: ‘Life-Saving’ Martha’s Rule To Expand To Emergency Departments Across England: What It Means

Sepsis is a life-threatening medical emergency that occurs when the body's response to an infection gets dysregulated, damaging its own tissues and organs. It can develop from infections affecting the lungs, urinary tract, skin or gastrointestinal system, as well as infections after a surgery.

Without timely treatment, sepsis can progress to organ failure and death. In severe cases, it can cause septic shock, in which blood pressure falls dangerously low and organs receive insufficient blood flow.

Stevens' case involved peritonitis, an inflammation of the tissue lining the abdominal cavity, followed by septic shock, according to the lawsuit.

Severe infection and septic shock can disrupt blood circulation and reduce oxygen delivery to tissues. When blood flow becomes critically inadequate, tissue can die, which is known as necrosis. In some cases, surgeons may need to amputate affected limbs to remove dead or severely damaged tissue and prevent further complications.

However, limb loss is not an inevitable outcome of sepsis. It represents a severe complication that can occur in some critically ill patients.

Warning Signs

The US Centers for Disease Control and Prevention identifies several possible signs of sepsis:

• Fever, shivering or feeling unusually cold
• Confusion or disorientation
• Rapid heart rate or a weak pulse
• Shortness of breath
• Clammy or sweaty skin
• Extreme pain or discomfort

After surgery, worsening abdominal pain, fever, unusual bleeding, wound discharge or a sudden deterioration in general health warrants urgent medical assessment. Symptoms should not be dismissed simply because a patient has recently undergone a procedure.

Sepsis requires immediate evaluation and treatment. Management may include antibiotics, intravenous fluids, support for organ function and, where necessary, surgery to control the source of infection.

Spain is seeing a rise in COVID-19 cases as the XFG variant, also known as American COVID, becomes the dominant circulating strain. Acute respiratory infections have reached epidemic levels, with COVID-19 and bronchiolitis contributing to the increase.

The Carlos III Institute’s Acute Respiratory Infection Surveillance System (SiVIRA) recorded 493.8 cases per 100,000 people between September 28 and October 4, up 3.3% from 478.2 the previous week.

According to Redacción Médica, infection intensity remains low despite the upward trend. COVID-19 incidence alone approached 120 cases per 100,000 people.

XFG Dominates COVID-19 Cases In Spain

The European Centre for Disease Prevention and Control (ECDC) estimated that XFG accounted for 54% of sequences reported by countries with sufficient data during weeks 34 and 35.

In Spain, the variant represented around 69% of those identified in primary care and 65% of hospital samples. However, the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) cautioned that the rise cannot be attributed to XFG alone.

Spain is also witnessing a rise in respiratory viruses, which reached 478.2 cases per 100,000 inhabitants between 21 and 27 September, well above the 373 the previous week and also above the 400 mark, which marks the start of an epidemic.

Estimates put the total incidence of Covid-19 at 119.2 cases, compared with 92.6 in the previous week. The rate of positive test results stands at 4.1 per cent for flu, 27.2 per cent for SARS-CoV-2 and 0.2 per cent for respiratory syncytial virus (RSV), which causes bronchiolitis.

Also read: ‘American Covid’ Strain Drives 50% Surge in UK Hospital Admissions: XFG Symptoms to Know

What Is The XFG Variant?

XFG is a recombinant Omicron lineage formed when two Omicron sublineages combined. The World Health Organization (WHO) classified it as a variant under monitoring in 2025 because of its growth advantage. It is not a variant of concern yet.

Although XFG has mutations in its spike protein, studies suggest its ability to evade immunity differs only slightly from that of other JN.1 descendants.

There is no evidence that XFG causes more severe illness than other circulating Omicron variants. However, increased transmission can still lead to more hospital admissions by raising the total number of infections.

XFG Symptoms

Read More: XFG COVID Variant: What India Should Watch As Cases Rise In UK And France

XFG has no distinctive symptoms that reliably separate it from other COVID-19 variants. Common symptoms include:

• Sore throat
• Runny or blocked nose
• Cough
• Fever or chills
• Headache and muscle aches
• Fatigue

Loss of smell or taste is less common than during the early pandemic. Symptoms alone cannot identify the variant causing an infection.

Why Are Cases Rising?

The Institute reported that possible contributors to rising infections include:

• Greater transmissibility of XFG
• Waning immunity from vaccination and previous infections
• Increased social contact after summer
• Seasonal patterns of recurring COVID-19 waves
• Multiple sublineages circulating simultaneously

The relative contribution of each factor remains uncertain.

COVID-19 Cases Rise In The UK And France

READ: COVID-19 Cases Rise In France, Vaccination Campaign Set To Start Next Week

United Kingdom: The UK Health and Security Agency recorded a staggering 230% jump in cases from August to September, rising from 1,374 to 4,589. Hospital admissions soared even more dramatically from 950 to 4,939 in the same period.

The National Health Service (NHS) advises calling 999 for medical emergencies, including severe breathing difficulties, coughing up blood, collapse, loss of consciousness or a first seizure. The agency has also advised Brits testing positive to isolate for at least five days, with under-18s needing just three days. Anyone with the virus should avoid contact with immunocompromised people for 10 days.

France: COVID-19 cases among people consulting general practitioners for acute respiratory infections in France reached 13 per 100,000 during September 21–27, up from nine the previous week, The Connexion reported.

This represented approximately 8,806 cases, compared with around 6,000 a week earlier.

Overall, acute respiratory infections reported by general practitioners rose from 103 to 151 cases per 100,000 people. Rhinoviruses accounted for 40% of samples, compared with 10% for COVID-19.